Ctrl (n = 43) | sPD (n = 60) | Asymptomatic LRRK2 mutation carriers (n = 51) | Symptomatic LRRK2 mutation carriers (n = 23) | |
---|---|---|---|---|
Age (y), mean ± SDa | 49 ± 18 | 57 ± 10 | 57 ± 14 | 60 ± 11 |
Gender (male), n(%)a | 19 (38.0%) | 36 (52.9%) | 26 (50%) | 6 (25%) |
Disease duration (y)b | NA | 4 (1–6) | NA | 7 (5–19) |
MoCAc | 27 (27–29) | 27 (25–28) | 27 (26–28) | 25 (23.7–27) |
H&Y | NA | 2 (2–2) | 0 (0–0) | 2 (2–3) |
UPDRS-IIId | NA | 24 (19–29) | 3 (0.25–5) | 24 (19.5–27) |
t-α-syn (pg/mL)e | 816 (596–1112) | 573 (466–710)*** | 617 (431–803)** | 608 (432–740)** |
o-α-syn (pg/mL)e | 161 (148–186) | 187.5 (170.5–219.8)** | 183 (160–230)** | 182 (146–196) |
pS129-α-syn (pg/mL)e | 116 (103–145) | 139 (114.25–163) | 121 (94–150) | 122 (106–145) |
tTau (pg/mL)f | 141.2 (89.6–201.3) | 134.7 (88.3–224.9) | 123.6 (86.7–236.4) | 113.5 (94.9–167.8) |
pTau (pg/mL)f | 12 (9–16) | 14.3 (9.6–21.7) | 14.7 (10.7–20.8) | 15.9 (10.5–22.4) |
Aβ-40 (pg/mL)f | 2506 (1967–3120) | 2595.7 (2193.7–3098.2) | 2776.2 (2287.6–4020.6) | 3048.9 (1959.3–3810.8) |
Aβ-42 (pg/mL)f | 517.9 (404.77–738) | 535.4 (405.11–662.6) | 580.3 (457.8–905.3) | 539.9 (410.9–880.9) |
IL-16g | 6.5 (4.9–8) | 5.1 (4–6.6)* | 5.1 (3.9–6.8) | 4.3 (2.8–5.3) |
TNF-αg | 3.3 (2.6–5.5) | 4.2 (2.4–6.5) | 5.5 (4.2–7.4)* | 5.5 (2.5–7.3) |